Cargando…
Fast-Acting Sublingual Zolpidem for Middle-of-the-Night Wakefulness
Sleep disorders (somnipathies) are conditions characterized by disruptions of sleep quality or of sleep pattern. They can involve difficulty falling asleep (prolonged sleep onset latency), difficulty staying asleep (disturbance of sleep maintenance), sleep of poor quality (unrefreshing), or combinat...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932650/ https://www.ncbi.nlm.nih.gov/pubmed/24649369 http://dx.doi.org/10.1155/2014/527109 |
_version_ | 1782304824455331840 |
---|---|
author | Pergolizzi, Joseph V. Taylor, Robert Raffa, Robert B. Nalamachu, Srinivas Chopra, Maninder |
author_facet | Pergolizzi, Joseph V. Taylor, Robert Raffa, Robert B. Nalamachu, Srinivas Chopra, Maninder |
author_sort | Pergolizzi, Joseph V. |
collection | PubMed |
description | Sleep disorders (somnipathies) are conditions characterized by disruptions of sleep quality or of sleep pattern. They can involve difficulty falling asleep (prolonged sleep onset latency), difficulty staying asleep (disturbance of sleep maintenance), sleep of poor quality (unrefreshing), or combinations of these and can lead to poor health and quality of life problems. A subtype of sleep-maintenance insomnia is middle-of-the-night wakefulness, a relatively common occurrence. Zolpidem, a nonbenzodiazepine benzodiazepine receptor agonist, allosterically modulates an ion channel and increases the influx of Cl(−), thereby dampening the effect of excitatory (sleep disrupting) input. Recently, product label changes to some zolpidem containing products have been implemented by the FDA in order to reduce the risk associated with their morning after residual side effects. A new formulation of zolpidem tartrate (Intermezzo) sublingual tablet, an approved product indicated exclusively for the treatment of middle-of-the-night wakefulness and difficulty returning to sleep, did not have its label changed. We present a short summary of its basic science and clinical attributes in light of the recent regulatory changes for zolpidem products. |
format | Online Article Text |
id | pubmed-3932650 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-39326502014-03-19 Fast-Acting Sublingual Zolpidem for Middle-of-the-Night Wakefulness Pergolizzi, Joseph V. Taylor, Robert Raffa, Robert B. Nalamachu, Srinivas Chopra, Maninder Sleep Disord Review Article Sleep disorders (somnipathies) are conditions characterized by disruptions of sleep quality or of sleep pattern. They can involve difficulty falling asleep (prolonged sleep onset latency), difficulty staying asleep (disturbance of sleep maintenance), sleep of poor quality (unrefreshing), or combinations of these and can lead to poor health and quality of life problems. A subtype of sleep-maintenance insomnia is middle-of-the-night wakefulness, a relatively common occurrence. Zolpidem, a nonbenzodiazepine benzodiazepine receptor agonist, allosterically modulates an ion channel and increases the influx of Cl(−), thereby dampening the effect of excitatory (sleep disrupting) input. Recently, product label changes to some zolpidem containing products have been implemented by the FDA in order to reduce the risk associated with their morning after residual side effects. A new formulation of zolpidem tartrate (Intermezzo) sublingual tablet, an approved product indicated exclusively for the treatment of middle-of-the-night wakefulness and difficulty returning to sleep, did not have its label changed. We present a short summary of its basic science and clinical attributes in light of the recent regulatory changes for zolpidem products. Hindawi Publishing Corporation 2014 2014-02-05 /pmc/articles/PMC3932650/ /pubmed/24649369 http://dx.doi.org/10.1155/2014/527109 Text en Copyright © 2014 Joseph V. Pergolizzi Jr. et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Pergolizzi, Joseph V. Taylor, Robert Raffa, Robert B. Nalamachu, Srinivas Chopra, Maninder Fast-Acting Sublingual Zolpidem for Middle-of-the-Night Wakefulness |
title | Fast-Acting Sublingual Zolpidem for Middle-of-the-Night Wakefulness |
title_full | Fast-Acting Sublingual Zolpidem for Middle-of-the-Night Wakefulness |
title_fullStr | Fast-Acting Sublingual Zolpidem for Middle-of-the-Night Wakefulness |
title_full_unstemmed | Fast-Acting Sublingual Zolpidem for Middle-of-the-Night Wakefulness |
title_short | Fast-Acting Sublingual Zolpidem for Middle-of-the-Night Wakefulness |
title_sort | fast-acting sublingual zolpidem for middle-of-the-night wakefulness |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932650/ https://www.ncbi.nlm.nih.gov/pubmed/24649369 http://dx.doi.org/10.1155/2014/527109 |
work_keys_str_mv | AT pergolizzijosephv fastactingsublingualzolpidemformiddleofthenightwakefulness AT taylorrobert fastactingsublingualzolpidemformiddleofthenightwakefulness AT raffarobertb fastactingsublingualzolpidemformiddleofthenightwakefulness AT nalamachusrinivas fastactingsublingualzolpidemformiddleofthenightwakefulness AT chopramaninder fastactingsublingualzolpidemformiddleofthenightwakefulness |